

Protalix BioTherapeutics, Inc.  
Form 8-K  
September 24, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): September 22, 2009**

**Protalix BioTherapeutics, Inc.  
(Exact name of registrant as specified in its charter)**

<b>Florida</b> <b>(State or other jurisdiction of incorporation)</b>	<b>000-33357</b> <b>(Commission File Number)</b>	<b>65-0643773</b> <b>(IRS Employer Identification No.)</b>
<b>2 Snunit Street</b> <b>Science Park, POB 455</b> <b>Carmiel, Israel</b> <b>(Address of principal executive offices)</b>		<b>20100</b> <b>(Zip Code)</b>
	<b>Registrant's telephone number, including area code +972-4-988-9488</b> <b>(Former name or former address, if changed since last report.)</b>	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EX-99.1

**Item 8.01. Other Events**

On September 22, 2009, Protalix BioTherapeutics, Inc. (the Company ) issued a press release reporting preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel ). A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated September 22, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: September 24, 2009

By: /s/ David Aviezer

Name:

David Aviezer, Ph.D.

Title: President and

Chief Executive Officer

3